News

Act 374 took effect August 1, 2026, the first state statute we can identify that legislates on peptides by name. The enacted R.S. 37:23.5 is narrower than the bill introduced: the Category 2 conditions, the FDA prohibited-list condition, and the API-sourcing requirement were all amended out before passage, leaving a plain federal-compliance standard. What survived restrains state licensing boards rather than authorizing anything — which is why it is better read as a state-level overlay on the 503A lane than as a fourth lane.

The FDA has proposed to bar outsourcing facilities from bulk-compounding semaglutide, tirzepatide, and liraglutide — the concrete current news. But “the rules changed” is too coarse: compounding runs through two separate federal channels, 503A (a pharmacy compounding for one patient) and 503B (bulk outsourcing), and they moved differently. Sort it into three lanes — FDA-approved drugs, compoundable peptides (503A/Category 1), and research-use-only peptides — and it’s clear which channel each rule touches. The count to keep straight: zero peptides are confirmed in Category 1; twelve were removed from Category 2, six were recommended, and removal isn’t authorization. Prof. Peptide’s lane — research peptides — is separate and unaffected by these specific actions.

Hearing that the FDA is loosening peptide rules and banning compounded GLP-1s in the same week isn’t a contradiction — they’re two separate regulatory tracks moving in opposite directions. Track 1: twelve peptides came off Category 2 and a panel recommended six for the 503A list (recommendations, not approvals). Track 2: the FDA proposed — not finalized — to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Plus a third layer, the states, which have moved on GLP-1s specifically. The unmissable point: removal from Category 2 is not authorization to compound, and nothing is legal to compound today that wasn’t yesterday.

The FDA’s Pharmacy Compounding Advisory Committee voted July 23–24 to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for the 503A Bulks List (8–6 and 7–5 splits) and rejected DSIP. But these are non-binding recommendations, not approvals — the FDA must still act through rulemaking, into 2027, with HHS sign-off. Nothing is legal to compound that wasn’t yesterday. Inside: the tallies, why the panel overruled its own scientists, the conflict-of-interest questions, and how Category 2, a PCAC vote, and the 503A list differ.

Recap of ENDO 2026 (Chicago, June 13–16): a GLP-1 physical-activity decline and the muscle-preservation angle, reassuring male-fertility data, a CagriSema meta-analysis (SUN-726), real-world adherence patterns, and Entera Bio’s preclinical oral peptides EB618 and EB612. Each finding is labeled by evidence stage with primary-source links.

A UC San Diego analysis in Nature Communications found semaglutide slowed multiple epigenetic-aging clocks (DunedinPACE ~9% slower; PCGrimAge −3.08 years) in a 32-week randomized, double-blind, placebo-controlled trial. The catch: it’s a secondary biomarker analysis in adults with HIV-associated lipohypertrophy — early, population-specific evidence, not proof of a longevity drug.

A peptide-antibody conjugate that activates GLP-1 while blocking GIP — the mirror image of tirzepatide — MariTide is now in an expanding Phase 3 program, including a trial switching patients off weekly GLP-1s.

The FDA found no clinical need to keep the three leading GLP-1 drugs on the 503B bulks list. A public comment window runs through June 29 — here’s what the proposal does, and doesn’t, cover.

Eli Lilly’s investigational triple agonist retatrutide produced 30.3% average weight loss at 104 weeks in the pivotal TRIUMPH-1 Phase 3 trial — comparable to bariatric surgery outcomes. Here’s the full breakdown of the topline data and what comes next.

The European Congress on Obesity (ECO2026) ran May 12-15 in Istanbul. Novo Nordisk, Eli Lilly, and Viking Therapeutics each presented new oral GLP-1 data — including a Wegovy pill sub-analysis showing 21.6% weight loss in early responders, Lilly’s maintenance trial results, and Viking’s Phase 2 VK2735 readout. Here’s what the data showed and why it matters.

The first Phase 3 readouts from retatrutide’s TRIUMPH and TRANSCEND-T2D programs are in. Here’s what TRANSCEND-T2D-1 and TRIUMPH-4 showed and what comes next.

The FDA published the official Federal Register notice for its July 23-24 Pharmacy Compounding Advisory Committee meeting, naming the seven peptides under review and the conditions each is being considered for.

The FDA posted a Federal Register notice considering lifting restrictions on seven Category 2 peptides, with an advisory panel scheduled for late July 2026. Here’s what it means for the research community.

RFK Jr. announced 14 peptides would return to legal compounding status — but the FDA hasn’t published the official list yet. Here’s what we know, what’s still pending, and what it means for researchers.

HHS Secretary Robert F. Kennedy Jr. announced an intent to move about 14 of 19 restricted peptides off the FDA’s Category 2 “do not compound” list — but removal from Category 2 is not the same as Category 1 placement, and none is yet confirmed compoundable.